Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581111 · ClinicalTrials.gov registry record · Phase 2
Naloxone for Optimizing Hypoxemia Of Lung Donors
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT02581111 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 199 participants.
The verdict
NCT02581111, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
Brain-dead patients who provide authorization for organ donation will be randomized to naloxone or placebo if baseline arterial blood gas (ABG) after initiation of OPO (Organ Procurement Organization) management reveals hypoxemia, as defined by the ratio of partial pressure of oxygen in arterial blood (PaO2) to fraction of inspired oxygen (FiO2) below 300 mm Hg, unless they have already been ruled-out for lung recovery. Investigators aim to assess whether naloxone improves oxygenation prior to organ recovery more than placebo.
Interventions
- DRUG Normal saline
- DRUG Naloxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581111
The ClinicalTrials.gov registry entry for NCT02581111 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT02581111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02581111 about?
NCT02581111 is a clinical study titled "Naloxone for Optimizing Hypoxemia Of Lung Donors". Brain-dead patients who provide authorization for organ donation will be randomized to naloxone or placebo if baseline arterial blood gas (ABG) after initiation of OPO (Organ Procurement Organization) management reveals hypoxemia, as defined by the ratio of partial pressure of oxygen in arterial blo...
What is the current status of trial NCT02581111?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2015-09. Estimated completion is 2017-09-25.
What interventions are being tested in trial NCT02581111?
The interventions under investigation include: Normal saline (DRUG), Naloxone (DRUG).
Who is sponsoring clinical trial NCT02581111?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.